regulated by acetylation and deacetylation. SIRT1 destabilizes p53 through catalyzing deacetylation of p53 at lysine 382, which weakens its DNA binding ability. (15, 16 ) Accordingly, cells derived from SIRT1 deficient mice and cells treated with siRNAs against SIRT1 show high levels of hyperacetylated p53, and a dominantnegative SIRT1 mutant increases p53-dependent transcriptional activity. (17) However, it is also known that p53 positively regulates SIRT1 transcription and loss of p53 impairs SIRT1 induction.
(18) Therefore, it is likely that p53 inactivation can reduce SIRT1 expression level through a negative feedback loop. As such, we elected to examine for possible correlation between SIRT1 and p53 in gastric cancer.
In order to determine whether genetic and expression alterations of the SIRT1 and p53 are involved in the development or progression of gastric cancer, somatic mutations and protein expression of the SIRT1 and p53 genes were analyzed in gastric adenocarcinomas.
Materials and Methods

Samples
One hundred seventy (n=170) formalin-fixed paraffinembedded gastric cancer specimens were obtained from the 
Immunohistochemistry for the SIRT1
For the immunohistochemical analysis, 2 μm sections were cut the day before use and stained according to standard protocols.
To maximize the signal on immunohistochemistry, two strategies were used in this study: antigen retrieval in citrate buffer and signal amplification with biotinylated tyramide. For the former, heat- 
Microdissection and DNA extraction
Since DNA extracted from formalin fixed paraffin embedded tissue is of low quality for mutational analysis, we extracted DNAs from 86 methacarn-fixed paraffin-embedded tissues, which were not included in our tissue microarray. These samples were also using Kodak X-OMAT film (Eastman Kodak, Rochester, NY, USA). DNAs showing mobility shifts were cut out from the dried gels and amplified for 35 cycles using the same primer set.
Sequencing of the PCR products was sequenced on the ABI prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
The Chi-square test for association was used to test the relationship between SIRT1 expression and the clinicopathologic parameters of gastric cancers. A P-value<0.05 was considered statistically significant.
Results
Immunohistochemistry of SIRT1 expression
Moderate to strong immunopositivity for SIRT1 was clearly marked on the nucleus of gastric cancer cells (Fig. 1) 
Mutation analysis of the SIRT1 and p53 gene
The presence of any mutations, possibly associated with aberrant SIRT1 expression, was examined using PCR-based SSCP and sequencing analysis. Expectedly, we found SIRT1 and p53 mutations in 2 and 12 cases, respectively. As shown in Fig. 2 and Table 3 Our study has shown that a high proportion of gastric carcinomas overexpressed SIRT1. However, there was no significant SIRT1 has well established anti-apoptotic activity and is presumed to act as an oncogene. However, a recent study Here, we found frequent nuclear overexpression of SIRT1 protein, and 2 and 12 somatic mutations of SIRT1 and p53 genes, respectively. Overexpression of SIRT1 protein was not associated with clinicopathologic parameters and p53 nuclear expression. The cases carrying SIRT1 mutation showed overexpression of SIRT1 protein and mutations of SIRT1 and p53 were mutually exclusive.
Although we did not perform functional analysis of SIRT1 mutations in this study, our results suggest that aberrant expression and genetic alterations of SIRT1 may contribute to the development of gastric cancer. Additional studies are needed to clarify the role of the SIRT1 in the pathogenesis of gastric cancers.
